News
BIIB
195.34
-0.57%
-1.11
Biogen’s Salanersen Win Adds New Dimension To SMA Growth Story
Simply Wall St · 1d ago
Biogen Advances BIIB115 in Post–Gene Therapy SMA: Early Signals for Long‑Term Growth
TipRanks · 1d ago
AbCellera appoints Victor Sandor to board as independent director
PUBT · 2d ago
Revolution Medicines Is Up 97% This Year: Here Are the Bull and Bear Cases for This Soaring Biotech Stock.
NASDAQ · 2d ago
BIIB Investors Have Opportunity to Join Biogen Inc. Fraud Investigation with the Schall Law Firm
Barchart · 2d ago
BUZZ-U.S. STOCKS ON THE MOVE -Honeywell, Broadcom, Carlyle
Reuters · 2d ago
BUZZ-U.S. STOCKS ON THE MOVE-UnitedHealth, Pinterest, Celcuity
Reuters · 2d ago
FDA Grants Breakthrough Therapy Designation To Biogen's Salanersen In Treating Muscular Atrophy
NASDAQ · 2d ago
BUZZ-Biogen up after FDA grants 'breakthrough' tag for neuromuscular disorder drug
Reuters · 3d ago
Biogen Gets FDA Breakthrough Designation for Spinraza Successor Salanersen
Dow Jones · 3d ago
Biogen granted Breakthrough Therapy Designation for salanersen by FDA
TipRanks · 3d ago
Biogen Says FDA Grants Salanersen Breakthrough Therapy Designation For Treatment Of Spinal Muscular Atrophy
Benzinga · 3d ago
BIOGEN’S SALANERSEN RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION FOR SPINAL MUSCULAR ATROPHY
Reuters · 3d ago
Biogen And UCB Present Positive PHOENYCS GO Data For DZP In Treating Lupus
NASDAQ · 3d ago
UCB, Biogen announce dapirolizumab pegol data at EULAR
TipRanks · 3d ago
UCB, Biogen Report New Lupus Drug Data at EULAR, Say Dapirolizumab Pegol Data Support Steroid Tapering
Benzinga · 3d ago
Mixed Lupus Win And Parkinson’s Setback Might Change The Case For Investing In Biogen (BIIB)
Simply Wall St · 3d ago
EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus
Barchart · 3d ago
Ocugen's Gene-Agnostic Eye Therapies Could Reshape Late-Stage Care
NASDAQ · 3d ago
Is OCGN Stock Worth the Risk Ahead of 2026-27 Eye Gene Therapy Data?
NASDAQ · 3d ago
More
Webull provides a variety of real-time BIIB stock news. You can receive the latest news about Biogen Inc through multiple platforms. This information may help you make smarter investment decisions.
About BIIB
Biogen Inc. is a biotechnology company. The Company is focused on discovering, developing and delivering therapies. It has a portfolio of medicines to treat Multiple Sclerosis (MS), has introduced an approved treatment for Spinal Muscular Atrophy (SMA), co-developed treatments to address a defining pathology of Alzheimer's disease and launched an approved treatment to target a genetic cause of Amyotrophic Lateral Sclerosis (ALS). It markets a drug approved in United States, European Union and certain international markets for the treatment of Friedreich Ataxia (FA) in adults and adolescents aged 16 years and older. It is focused on advancing its pipeline in neurology, specialized immunology and rare diseases. Its marketed products include VUMERITY, TYSABRI, TECFIDERA, AVONEX and PLEGRIDY for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of FA, and QALSODY for the treatment of ALS. Its commercialized products also include EMPAVELI and SYFOVRE.